CAL
KROS icon

Capital Advisors Ltd’s Keros Therapeutics KROS Stock Holding History

Capital Advisors Ltd’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Hold
30
– – ﹤0.01% 1480
2026
Q1 		$0 Hold
30
– – ﹤0.01% 1493
2025
Q4 		$1K Hold
30
– – ﹤0.01% 1222
2025
Q3 		$0 Hold
30
– – ﹤0.01% 1468
2025
Q2 		$0 Buy
30
+14
+88% +$189 ﹤0.01% 1499
2025
Q1 		$0 Buy
+16
New +$186 ﹤0.01% 1469

Other funds holding KROS

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Capital Advisors Ltd's KROS Position: Q2 2026 in Review

Capital Advisors Ltd held its Keros Therapeutics (KROS) position steady in Q2 2026 at 30 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1480.

Capital Advisors Ltd first reported a position in KROS in Q1 2025 and has held it in 6 quarters since. The position peaked at $1K in Q4 2025. 7 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Capital Advisors Ltd held 30 shares of Keros Therapeutics worth $0 as of Q2 2026.
  • Capital Advisors Ltd left its Keros Therapeutics share count unchanged in Q2 2026.
  • Keros Therapeutics made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #1480 holding.
  • Capital Advisors Ltd first reported a position in Keros Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Capital Advisors Ltd's Keros Therapeutics position peaked at $1K in Q4 2025.
  • 7 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.